
ELTX Stock Forecast & Price Target
ELTX Analyst Ratings
Bulls say
Elicio Therapeutics is actively working on developing a promising immunotherapy vaccine, ELI-002, for KRAS-mutated cancers, particularly for patients with advanced stages of the disease. The company's focus on targeted delivery through their proprietary AMP technology and the use of a global Phase 3 trial to compare ELI-002 to other treatments demonstrates their commitment to advancing cancer treatment. Additionally, the expertise of the lead researcher in immunotherapy is a positive sign for the potential success of the vaccine.
Bears say
Elicio Therapeutics is a clinical-stage biotechnology company with a promising immunotherapy platform, but challenges lie ahead. While their 7P phase 1a trial showed a significant dose-response relationship with strong T cell responses and biomarker clearance in some patients, the sample size was small and the 7P trial was still maturing at the data cutoff. Additionally, the company faces regulatory and financial risks, as success in phase 2 testing may not guarantee regulatory approval and the company may need to raise additional capital to continue development.
This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELTX Analyst Forecast & Price Prediction
Start investing in ELTX
Order type
Buy in
Order amount
Est. shares
0 shares